We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Potential Biomarkers Identified for Symptoms of Lupus in the Brain
News

Potential Biomarkers Identified for Symptoms of Lupus in the Brain

Potential Biomarkers Identified for Symptoms of Lupus in the Brain
News

Potential Biomarkers Identified for Symptoms of Lupus in the Brain

Credit: Сергей Катышкин/ Pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Potential Biomarkers Identified for Symptoms of Lupus in the Brain"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A globally renowned expert in autoimmune diseases and systemic lupus erythematosus (SLE) at the University of Houston has identified potential biomarkers for neuropsychiatric symptoms of lupus. Lupus is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs.


While most people with lupus experience a variety of symptoms that include fatigue, skin rashes, fever, and pain or swelling in the joints, about half of people with SLE suffer neuropsychiatric symptoms. Those include seizures, aseptic meningitis, acutely confused states, cerebrovascular disease psychosis and mood disorders. 


“The diagnosis of neuropsychiatric lupus is difficult because the neurological symptoms could very well be due to other causes. As no gold-standard diagnostic test exists for neuropsychiatric systemic lupus erythematosus (NPSLE), we executed a broad screen of NPSLE cerebrospinal fluid using an aptamer-based platform,” reports Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, in the journal Arthritis & Rheumatology. Aptamers are short sequences of nucleic acids that can be further selected based on their binding specificities. Commercially available libraries of aptamers allow comprehensive screening of >1000 human protein targets, representing some of the largest screening platforms currently available in targeted proteomics. 


Mohan’s team screened more than 1,100 proteins in the fluid surrounding the brains of neuropsychiatric lupus patients and identified a few proteins that could potentially be used to diagnose neuropsychiatric lupus. The proteins that showed up in most samples are CSF Lipocalin-2, M-CSF, IgM and complement C3. 


“These proteins emerged as promising cerebrospinal fluid biomarkers of NPSLE with diagnostic potential,” Mohan reported. “Elevated CSF C3 was associated with acute confusional state. Eleven molecules elevated in the fluid exhibited concordant elevation in the choroid plexus, suggesting shared origins.”


Neuropsychiatric events occur most frequently early during the disease course in most cases, either as a presenting symptom or within the first five years of disease onset. 


Cerebrospinal fluid samples used in this study were provided by collaborators John Hanly from Dalhousie Lupus Clinic, Halifax, Nova Scotia, Canada and C.C. Mok from Tuen Mun hospital in Hong Kong, China. Laboratory studies were carried out by UH researcher Kamala Vanarsa in Mohan’s lab.


"We believe proteomic investigations of blood and cerebrospinal fluid will eventually lead to the fabrication of a serum or cerebrospinal fluid-based diagnostic panel that permits accurate diagnosis of NPSLE, with significantly higher specificity for this disease, compared to other neuroinflammatory diseases or infections,” said Mohan.  


Reference: Vanarsa K, Sasidharan P, Duran V, et al. Aptamer-based screen of Neuropsychiatric Lupus cerebrospinal fluid reveals potential biomarkers that overlap with the choroid plexus transcriptome. Arthritis Rheumatol. 2022. doi: 10.1002/art.42080


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement